Selective serotonin reuptake inhibitors (SSRIs) are extensively used for the treatment of depression. Aside from their antidepressant properties, they provoke a deficit in paradoxical sleep (PS) that is most probably mediated by the transporter blockade-induced increase in serotonin concentration in the extracellular space. Such an effect can be accounted for by the action of serotonin at various types of serotonergic receptors involved in PS regulation, among which the 5-HT 1A and 5-HT 1B types are the best candidates. According to this hypothesis, we examined the effects of citalopram, the most selective SSRI available to date, on sleep in the mouse after inactivation of 5-HT 1A or 5-HT 1B receptors, either by homologous recombination of their encoding genes, or pharmacological blockade with selective antagonists. For this purpose, sleep parameters of knockout mice that do not express these receptors and their wild-type counterparts were monitored during 8 h after injection of citalopram alone or in association with 5-HT 1A or 5-HT 1B receptor antagonists. Citalopram induced mainly a dose-dependent inhibition of PS during 2-6 h after injection, which was observed in wild-type and 5-HT 1B À/À mice, but not in 5-HT 1A À/À mutants. This PS inhibition was fully antagonized by pretreatment with the 5-HT 1A antagonist WAY 100635, but only partially with the 5-HT 1B antagonist GR 127935. These data indicate that the action of the SSRI citalopram on sleep in the mouse is essentially mediated by 5-HT 1A receptors. Such a mechanism of action provides further support to the clinical strategy of antidepressant augmentation by 5-HT 1A antagonists, because the latter would also counteract the direct sleep-inhibitory side-effects of SSRIs.
INTRODUCTION
Selective serotonin reuptake inhibitors (SSRIs) are the most frequently prescribed drugs in anxiodepressive disorders. Since SSRIs produce a tonic elevation of serotonin levels in the extracellular space (Fuller, 1994; Malagié et al, 1995) , their therapeutic effect is probably mediated, at least in part, by action at various levels of the serotonergic system, notably at serotonergic receptors (Barnes and Sharp, 1999) . In particular, it has been proposed that the antidepressant effects of SSRIs would be related to desensitization of somatodendritic 5-HT 1A and terminal 5-HT 1B autoreceptors (Blier et al, 1987; Artigas et al, 1994 Artigas et al, , 2001 Pineyro and Blier, 1999) , which is induced by and participates indirectly in the increase in 5-HT concentration in the extracellular space (Gartside et al, 1995 (Gartside et al, , 1999 Sharp et al, 1997; Trillat et al, 1998; Adell et al, 2001; Malagié et al, 2001) .
Another well-known action of SSRIs is their effects on sleep and wakefulness. Indeed, in several species and notably the rat (Pastel and Fernstrom, 1987; Ursin et al, 1989; Lelkes et al, 1994; Maudhuit et al, 1994; Neckelmann et al, 1996b) , the hamster (Gao et al, 1992) , and also in humans (Van Bemmel et al, 1993; Hendrickse et al, 1994) , the most consistent action of SSRIs is a reduction of paradoxical sleep (PS), which is sometimes associated with an enhancement of wakefulness (W) and a secondary increase in slow wave sleep (SWS) (Maudhuit et al, 1994; Ursin, 2002) . In the same manner, systemic treatment with selective agonists at 5-HT 1A and 5-HT 1B receptors induces an inhibition of PS and an enhancement of wakefulness, notably in rodents (Dzoljic et al, 1992; Tissier et al, 1993; Bjorvatn and Ursin, 1994; Monti et al, 1995; Bjorvatn et al, 1997; Boutrel et al, 1999 Boutrel et al, , 2002 . In contrast, inactivation of 5-HT 1A and 5-HT 1B receptors (notably in mice with genetic deletions targeted at these receptors) facilitates the expression of PS (Boutrel et al, 1999 (Boutrel et al, , 2002 . Altogether, these data strongly suggest that 5-HT 1A and/or 5-HT 1B receptors, because they are activated by extracellular 5-HT, might mediate the action of SSRIs on sleep and wakefulness.
However, this hypothesis has still to be validated because (i) 5-HT 1A receptor antagonists were reported to be unable to prevent the effects of SSRIs on sleep or wakefulness (Bjorvatn et al, 1992; Neckelmann et al, 1996a) and (ii) to date, no study has been published with respect to the possible involvement of 5-HT 1B receptors in PS inhibition by SSRIs.
These considerations led us to address this question by using knockout mice that do not express 5-HT 1A or 5-HT 1B receptors (Saudou et al, 1994; Ramboz et al, 1998) . We analyzed the effects of citalopram, the most selective SSRI currently available (Hyttel, 1982; Milne and Goa, 1991) , on sleep-wakefulness cycles in 5-HT 1A and 5-HT 1B knockout mice and their wild-type counterparts. In addition, we investigated whether pharmacological blockade of either 5-HT 1A or 5-HT 1B receptors with selective antagonists could prevent the effects of citalopram on sleep in the mouse.
MATERIALS AND METHODS

Animals
All the procedures involving animals and their care were conducted in conformity with the institutional guidelines that are in compliance with national and international laws and policies (council directive 87-848, October 19, 1987, Ministère de l'Agriculture et de la Forêt, Service vétérinaire de la santé et de la protection animale, permissions 75-116 to MH and 75-125 to JA). All mice were of the same 129/Sv genetic background. They were produced in the laboratory from homozygous breeding of wild-type and mutant (5-HT 1A À/À and 5-HT 1B À/À) strains (Saudou et al, 1994; Ramboz et al, 1998; Boutrel et al, 1999 Boutrel et al, , 2002 , and housed in standard animal care facilities (see below).
Surgery
At 2-3 months of age (body weight: 21-27 g), male wild-type and mutant 5-HT 1A À/À and 5-HT 1B À/À mice were implanted under sodium pentobarbital anesthesia (70-75 mg/kg i.p.) with the classical set of electrodes for polygraphic sleep monitoring, as previously described (Boutrel et al, 1999) . In brief, EEG electrodes were inserted through the skull onto the dura over the right cerebral cortex (2 mm lateral and 4 mm posterior to bregma) and over the cerebellum (at midline, 2 mm posterior to lambda), EOG electrodes were positioned subcutaneously on each side of the orbit, and EMG electrodes were inserted into the neck muscles. All electrodes were anchored to the skull with super-bond cement (Limoge-Lendais et al, 1994) , and soldered to a mini-connector secured with acrylic cement. After completion of surgery, animals were housed in individual cages (20 Â 20 Â 30 cm 3 ) and maintained under standard laboratory conditions: 12-12 h light-dark cycle (light on at 07:00 am), 24 7 11C ambient temperature, food and water ad libitum. The animals were allowed at least 10 days to recover and habituate to the recording conditions.
Pharmacological Treatments
Drugs were dissolved in 0.1 ml of saline and injected intraperitoneally (i.p.) between 9:30 and 10:00 am. In case of combined treatments, the antagonist or saline was injected 15 min prior to citalopram. For baseline data, mice were injected with saline only, in single or combined treatment, as appropriate. A washout period of at least 3 days was allowed between two consecutive treatments. One series of animals was used to analyze the effects of citalopram alone, while another one was used in experiments with combined treatments. In both series, each animal received all doses and compounds, in a counter-balanced fashion. However, some recordings were discarded from the results because of insufficient quality. Thus, the number of tests finally contributing to the data was comprised between 4 and 10.
Polygraphic Recording
Polygraphic sleep monitoring was started just after the injection(s) and continued during 8 h thereafter.
Data Analysis and Statistics
Recordings were scored manually every 15 s epoch using the classical criteria for mice (Boutrel et al, 2002) . The effects of each treatment on the states of vigilance (W, SWS, PS) were analyzed for every 2 h period after injection, and were expressed (mean 7 SEM) as minutes and as percentage of baseline (injection of saline). Statistical analyses were performed using ANOVA for the factors treatment and strain of mice. In case of significance, this ANOVA was followed by a post hoc Fisher test or a paired Student's t-test as appropriate, in order to determine statistical significance of the effect of each dose of a given compound. 
RESULTS
Pharmacological Blockade of the Serotonin Transporter
In wild-type mice, blockade of the 5-HT transporter by citalopram induced a significant decrease in PS amounts, which lasted for 2-6 h after the injection (Figure 1 ). This effect was dose-dependent (ANOVA, F 3,21 ¼ 22.9 and 14.7, po0.0001; and F 3,21 ¼ 2.7, p ¼ 0.06 for the three successive 2 h periods after injection, respectively), and significant for the doses of 5 and 10 mg/kg of citalopram until 4 h (p ¼ 0.0005, n ¼ 7) and 6 h (p ¼ 0.01, n ¼ 5) after treatment, respectively. This citalopram-induced PS reduction was accounted for by an increase in PS latency (150.3 7 7.2 and 157.4 7 13.7 min for 5 and 10 mg/kg vs 68.8 7 10.8 and 63.8 7 13.5 min at baseline, respectively; means 7 SEM for seven and five tests, respectively, po0.01), and a decrease in the number of episodes with no significant modification of their mean duration (54 7 4 and 62 7 7 s during 4 h after 5 5-HT 1A/1B mediated paradoxical sleep inhibition by SSRI C Monaca et al and 10 mg/kg of citalopram, compared to 54 7 6 and 57 7 6 s after saline, respectively). After this initial decrease, PS amounts returned progressively to baseline values (Figure 1 ). Citalopram induced no modification of W, but a slight enhancement of SWS was observed between the 4th and the 6th hour after treatment with the dose of 1 mg/kg (Figure 1) .
In 5-HT 1B knockout mice, citalopram also produced a dose-dependent decrease in PS amounts during the first 4 h after injection (ANOVA, 0-2 h: F 3,19 ¼ 4.1, p ¼ 0.02 and 2-4 h: F 3,19 ¼ 6.7, p ¼ 0.003) (Figure 2 ). This effect was not significantly different from that in wild-type mice (ANOVA for factor strain: F 1,40 ¼ 0.90, p ¼ 0.35 and F 1,40 ¼ 0.004, p ¼ 0.95, for the 0-2 and 2-4 h periods after treatment, respectively) ( Figure 2 vs Figure 1 ). It was because of an increase in PS latency (103.5 7 12.1 for 10 mg/kg vs 48.7 7 5.7 min after saline, n ¼ 4, po0.001), and a decrease in the number of PS episodes with no modification of their mean duration (57 7 6 and 62 7 7 s during 4 h after 5 and 10 mg/kg of citalopram, compared to 57 7 6 and 60 7 4 s after saline, respectively; means 7 SEM for eight and five tests, respectively).
In contrast, in 5-HT 1A knockout mice, citalopram induced a lesser decrease of PS amounts, which was observed only during the first 2 h after the injection (ANOVA: F 3,18 ¼ 6.3, p ¼ 0.004), and reached statistical significance only for the highest dose tested, 10 mg/kg (p ¼ 0.006, n ¼ 4) (Figure 2 ). Like that observed in wild-type mice, this PS decrease was accounted for by an increase in PS latency (106.9 7 15.7 vs 51.3 7 5.4 min after saline, n ¼ 4, po0.001), and by a reduced number of PS episodes with no significant modifications of their mean duration (68 7 8 s for 10 mg/kg, vs 66 7 11 s at baseline, n ¼ 4). However, even at this highest dose, PS reduction caused by citalopram was significantly less in 5-HT 1A À/À mutants than in both wild-type and 5-HT 1B À/À mice (ANOVA for PS amounts across strains: F 2,58 ¼ 32.0 and 22.8, po0.0001 during 0-2 and 2-4 h after injection, respectively) ( Figure 2 vs Figure 1) .
Finally, no significant modifications of W or SWS were observed after citalopram administration (1, 5, or 10 mg/kg i.p.) in 5-HT 1B À/À and 5-HT 1A À/À knockout mice (not shown).
Blockade of the Serotonin Transporter After Pharmacological Inactivation of 5-HT 1A or 5-HT 1B Receptors
Pretreatment with the selective 5-HT 1A receptor antagonist, WAY 100635 (0.5 mg/kg i.p.), prevented the PS inhibitory effect of citalopram (5 mg/kg i.p.) in wild-type mice (Table 1 and Figure 3) . Similar data were obtained in 5-HT 1B À/À mutants. In contrast, in 5-HT 1A À/À mice, no significant differences in PS amounts were observed whether or not WAY 100635 was injected before citalopram (p ¼ 0.50, n ¼ 5) (Table 1 and Figure 3) . A significant enhancement of SWS and concomitant decrease in W were also observed in wild-type mice only, during 2 h post-treatment (Table 1) . 
5-HT 1A/1B mediated paradoxical sleep inhibition by SSRI C Monaca et al
Pretreatment with the 5-HT 1B receptor antagonist, GR 127935 (1 mg/kg i.p.), did not induce any modifications of the effects of citalopram on PS amounts in any strain, except for a partial prevention of PS inhibition in wild-type mice for the first 2 h after injection of the SSRI (Table 1) . This combined treatment induced during 4 h a decrease in the amounts of PS in both wild-type and 5-HT 1B À/À mice, and no modifications in 5-HT 1A À/À mutants, these effects being similar to those observed after injection of citalopram alone (Figure 3) .
DISCUSSION
The present data indicate that, in the mouse, blockade of the serotonin transporter by citalopram induces an inhibition of PS with no major modifications of the other states of vigilance. This action appears to be mediated mainly through 5-HT 1A receptor stimulation resulting from the increase in extracellular 5-HT levels caused by 5-HT reuptake inhibition.
The citalopram-induced decrease in PS that we report herein for the first time in the mouse is similar to that previously described in other rodents with various SSRIs (Pastel and Fernstrom, 1987; Ursin et al, 1989; Gao et al, 1992; Maudhuit et al, 1994; Neckelmann et al, 1996b; Ursin, 2002) . In addition, mice exhibited after treatment with moderate doses of citalopram a slight secondary increase in SWS amounts (see Figure 1 and Table 1), which was also found in rats (Ursin et al, 1989; Maudhuit et al, 1994) . However, in contrast to the latter studies, no modifications of wakefulness were observed herein.
The PS inhibition induced by the SSRI citalopram is most probably the consequence of the enhancement of extracellular 5-HT levels resulting from blockade of the amine reuptake (Fuller, 1994; Malagié et al, 1995; Fabre et al, 2000) . Among the receptors at which 5-HT in excess could act to induce PS inhibition, the 5-HT 1A and 5-HT 1B types appeared as the most relevant candidates (Dzoljic et al, 1992; Tissier et al, 1993; Bjorvatn and Ursin, 1994; Monti et al, 1995; Bjorvatn et al, 1997; Boutrel et al, 1999 Boutrel et al, , 2002 . Indeed, we can conclude from the present study that 5-HT 1A receptors are primarily involved in such a PS inhibition because the effect of citalopram on sleep was markedly reduced in 5-HT 1A À/À, but globally unchanged in 5-HT 1B À/À, mutants compared to wild-type mice. The almost complete loss of citalopram action in 5-HT 1A À/À mutants cannot be accounted for by a downregulation of the transporter itself because only mild changes of 5-HT 1A/1B mediated paradoxical sleep inhibition by SSRI C Monaca et al the latter were observed in knockout vs wild-type animals, notably in the brainstem (Ase et al, 2001 ), a key area for 5-HT-mediated PS regulation (Horner et al, 1997; Bjorvatn and Ursin, 1998) . Thus, the presence of functional 5-HT 1A receptors seems to be a prerequisite for the effect of citalopram on sleep, at least at moderate doses. Indeed, this effect was abolished not only in 5-HT 1A À/À mutants but also in wild-type mice after pharmacological blockade of 5-HT 1A , but not 5-HT 1B receptors. The question can be raised of whether the citalopraminduced PS inhibition could be secondary to a decrease in core temperature produced by this drug (Goodrich, 1983; Oerther and Ahlenius, 2001) . However, in the rat, citalopram-induced hypothermia can be prevented by pretreatment with either 5-HT 1A or 5-HT 1B receptor antagonists (Oerther and Ahlenius, 2001 ), whereas in wild-type mice, citalopram-induced PS inhibition could be antagonized by blockade of 5-HT 1A but not 5-HT 1B receptors (Figure 3 , Table 1 ). This difference strongly suggests that the effects of citalopram on PS are probably not secondary to its effects on core temperature. However, replication on wild-type and 5-HT 1A À/À/5-HT 1B À/À mutant mice of the study performed by Oerther and Ahlenius (2001) in rats should provide further answer to this question.
In line with previous studies (Boutrel et al, 1999 (Boutrel et al, , 2002 , the data obtained herein with the selective 5-HT 1A receptor antagonist WAY 100635 (Fletcher et al, 1996) associated with citalopram (see Table 1 ) confirm that this receptor type mediates a tonic inhibition of PS in the mouse (Boutrel et al, 2002) . Indeed, as expected from such a 5-HT 1A receptormediated physiological control of PS, blockade of 5-HT 1A receptors by WAY 100635 promoted PS in wild-type mice, when this antagonist was administered alone (Boutrel et al, 2002) or in combination with citalopram ( Figure 3 , Table 1 ). Indeed, in the latter case, PS amounts could not be affected by citalopram (because of the blockade of 5-HT 1A receptors) and only the enhancing effect of WAY 100635 (see Boutrel et al, 2002) was observed. However, these data are at variance with those obtained in rats where other failed to oppose the action of SSRIs on sleep (Bjorvatn et al, 1992; Neckelmann et al, 1996a) . The antagonist properties of the latter ligands at various receptors in addition to 5-HT receptors (Claustre et al, 1991; Hodgkiss et al, 1992; Hamon, 1997) and/or the use of different species, might possibly explain such differences compared to the present data obtained with the highly selective 5-HT 1A antagonist WAY 100635.
At the doses used, citalopram after 5-HT 1A receptor blockade in wild-type mice induced an increase of PS during 2 h, whereas in the absence of 5-HT 1A receptor expression, that is, in 5-HT 1A À/À mutants, it induced a slight PS decrease (Table 1) . One probable explanation of this difference is that in the first case one deals with a clearcut pharmacological effect of WAY 100635 (Boutrel et al, 2002) , whereas in 5-HT 1A À/À mutants, adaptive phenomena might have occurred, notably at the level of 5-HT receptors. Indeed, 5-HT 1B receptors were found to be supersensitive in 5-HT 1A À/À mutants (Boutrel et al, 2002) , and such a functional change might account, at least in part (see below), for the slight PS decrease observed after citalopram treatment (Table 1 ). In the whole, these data further support the idea that constitutive knock out of a specific gene does not produce exactly the same effects as the pharmacological blockade of the corresponding encoded protein.
In contrast to the effects reported herein on sleep regulations, it has been shown that combined treatment with 5-HT 1A antagonists and 5-HT reuptake inhibitors potentiated the effects of the latter drugs, at least with respect to 5-HT release in the hippocampus, food intake, and nociception (Hjorth, 1996; Trillat et al, 1998; Ardid et al, 2001) . Such a facilitatory effect of 5-HT 1A antagonists can be interpreted as resulting from the blockade of somatodendritic 5-HT 1A autoreceptors from which 5-HT can trigger a negative control on serotonergic cell firing, notably after citalopram treatment (Evrard et al, 1999) . With regard to sleep, WAY 100635 did not potentiate the action of citalopram, which confirms that the 5-HT 1A -mediated action of 5-HT on sleep involves 5-HT 1A receptors that differ from somatodendritic 5-HT 1A autoreceptors. Indeed, clear-cut evidence of the implication of postsynaptic 5-HT 1A receptors in the 5-HT-mediated inhibitory control of PS has already been reported in rats (Tissier et al, 1993) . Further studies suggested that these receptors are located in specific brainstem nuclei (Horner et al, 1997; Bjorvatn and Ursin, 1998) .
Interestingly, blockade of 5-HT reuptake by citalopram had almost the same effect on PS in wild-type and 5-HT 1B À/À mutant mice. This observation is in line with recent data showing that the molecular target of citalopram, the 5-HT transporter, is not modified in the brainstem (Ase et al, 2001 ) and only slightly enhanced in the nucleus raphe dorsalis (Evrard et al, 1999 ) of 5-HT 1B À/À mutants compared to their wild-type counterparts. We observed that PS amounts were largely reduced after citalopram treatment whether or not 5-HT 1B receptors were functional, that is, in 5-HT 1B À/À mutants and in wild-type mice pretreated with either saline or the 5-HT 1B antagonist GR 127935 (Pauwels, 1997) . Accordingly, it can be concluded that, in contrast to 5-HT 1A receptors, 5-HT 1B receptors do not play a crucial role in the inhibitory effect of citalopram on PS. Nevertheless, some modulation of this effect through the latter receptors cannot be excluded. In particular, it has to be emphasized that PS inhibition induced by treatment with saline+citalopram (5 mg/kg) was significant for only 2 h in 5-HT 1B À/À mutants, whereas it lasted for 4 h in wildtype mice (Table 1 ); in addition, the 5-HT 1B antagonist, GR 127935, partly reversed the action of citalopram in the latter animals (Table 1, Figure 3 ). On the other hand, PS inhibition following treatment with 10 mg/kg of citalopram in 5-HT 1A À/À mice (see Figure 2 ) might result from activation of 5-HT 1B receptors, inasmuch as PS in these mutant mice was found to be more sensitive to 5-HT 1B receptor agonists (Boutrel et al, 2002) . Meanwhile, the fact that 5-HT 1B À/À mutants exhibited some increase in PS amounts under baseline conditions compared to wild-type mice (see Table 1 ) confirms that 5-HT 1B receptors are involved in a tonic inhibition of PS in the mouse (Boutrel et al, 1999) . However, overall comparison of the respective effects of 5-HT 1B vs 5-HT 1A receptor inactivation on PS under baseline conditions as well as after citalopram treatment (see Table 1 ) clearly indicates that 5-HT 1A much 5-HT 1A/1B mediated paradoxical sleep inhibition by SSRI C Monaca et al more than 5-HT 1B receptors mediate the 5-HT inhibitory control of this sleep stage in the mouse. To conclude, given that insomnia, one cardinal symptom of depression, may be exacerbated by SSRIs, notably at initiation of the treatment (Levitan et al, 2000; Londborg et al, 2000) , the present data provide further support to the therapeutic strategy consisting of the association of these antidepressants with 5-HT 1A antagonists (Artigas et al, 1994) . Indeed, such combined treatments would simultaneously accelerate and/or augment the antidepressive action (Artigas et al, 1994 Blier and Bergeron, 1995; Stahl, 1998; Adrien, 2002) , and limit the sleep-inhibitory effect of of SSRIs (Thase, 2000) .
